ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2041

Baseline Clinical and Laboratory Features of IgG4-Related Disease: Retrospective Japanese Multicenter Study of 333 Cases

Kazunori Yamada1, Motohisa Yamamoto2, Takako Saeki3, Ichiro Mizushima4, Shoko Matsui5, Hiroki Takahashi6, Mitsuhiro Kawano7 and Shigeyuki Kawa8, 1Division of Rheumatology,, Kanazawa University Hospital, Kanazawa, Japan, 2First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, 3Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, 4Kanazawa University Hospital, Kanazawa, Japan, 5Health Administration Center, University of Toyama, Toyama, Japan, 6epartment of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, 7Division of Rheumatology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, 8Center for Health, Safety and Environmental Management, Shinshu University, Matsumoto, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical research and immunoglobulin (IG)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Oral Session II

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a widely recognized systemic inflammatory disorder. However, owing to its extremely diverse clinical picture, each clinician encounters a clinically distinct patient (pt) population depending on his/her specialty, and it is difficult to avoid institutional bias in a single center. This prompted us to conduct a relatively large-scale multicenter study with well-experienced physicians of IgG4-RD including rheumatologists, gastroenterologists, pulmonologists and nephrologists. The purpose of this study is to clarify the baseline clinical and laboratory features of IgG4-RD using a relatively large-scale cohort of 333 IgG4-RD pts.

Methods: Between 2001 and 2014, we retrospectively evaluated 333 pts with IgG4-RD in five institutions. The diagnosis of IgG4-RD was made based on the comprehensive diagnostic criteria or criteria of each organ. We analyzed the serum levels of IgG, IgG4, C3, C4, CH50 and CRP, the affected organs, the target organs for biopsy and treatment. We also determined the prevalence of diabetes mellitus (DM) and malignancy.

Results: Two hundred and four pts were male, and 129 were female (male 61.3%). The mean age was 63.8 years (range 25-91). At diagnosis, mean serum IgG and IgG4 were 2404 mg/dL and 755 mg/dL respectively. Serum IgG4 was elevated in 317 of 332 (95.5%). Hypocomplementemia was seen in 137 of 327 (41.9%), with pts with kidney lesion showing an especially high frequency (59.5% vs. 36.3%, p<0.001). Serum level of CRP was less than 1.0 mg/dL in 90.2%. Mean number of organs involved was 3.2 (range 1-11); salivary gland (SG) was the most frequently involved organ (72.3%), followed by lacrimal gland (LG), pancreas, retroperitoneum (RP)/periaorta, kidney, and lung. Single organ involvement excluding lymph nodes was seen in 63 of 333 (18.9%), with the most frequently affected organs being SG followed by LG. RP/periaorta, lung and kidney were more frequently affected in males than in females, whereas LG and SG were more frequently affected in females than in males. Biopsy was performed in 270 of 333 (81.1%), with SG 45.1%, lung 16.7%, pancreas 15.3%, kidney 15.2%. Corticosteroid therapy was administered to 248 of 313 (79.2%), and the mean initial dose of prednisolone was 30.5 mg/day. The prevalence of DM was significantly higher in those with than without AIP (47.0% vs. 30.0%, p=0.005). The prevalence of malignancy was 16.8%.

Conclusion: The present study clarified the organs most frequently affected by IgG4-RD by a retrospective multicenter study. In addition, we reconfirmed the high frequency of hypocomplementemia in pts with kidney lesion. Moreover, in more than 95% of pts, serum elevated IgG4 levels were useful for the diagnosis of IgG4-RD.


Disclosure: K. Yamada, None; M. Yamamoto, None; T. Saeki, None; I. Mizushima, None; S. Matsui, None; H. Takahashi, None; M. Kawano, None; S. Kawa, None.

To cite this abstract in AMA style:

Yamada K, Yamamoto M, Saeki T, Mizushima I, Matsui S, Takahashi H, Kawano M, Kawa S. Baseline Clinical and Laboratory Features of IgG4-Related Disease: Retrospective Japanese Multicenter Study of 333 Cases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/baseline-clinical-and-laboratory-features-of-igg4-related-disease-retrospective-japanese-multicenter-study-of-333-cases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-clinical-and-laboratory-features-of-igg4-related-disease-retrospective-japanese-multicenter-study-of-333-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology